Drug Profile
Research programme: adoptive cell therapeutics - Immatics
Alternative Names: ACTallo® γδ T cells; ACTolog® T-cell products; IMA 300Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Immatics US
- Developer Immatics US; Oxford BioMedica
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 07 Jun 2022 Immatics in-licenses gene editing CRISPR technology from Editas Medicine
- 02 Jun 2022 Bristol Myers Squibb and Immatics agree to co-develop TCR-T and/or CAR-T programs in USA for Solid tumours